Key result
Concurrent high-dose rosuvastatin and clarithromycin linked to severe rhabdomyolysis and marked transaminase elevation.
Why the study?
Rosuvastatin is considered to have a low risk of interactions with macrolides and co-administration with clarithromycin is not contraindicated, but rare cases of severe toxicity have been reported.
Does concurrent use of high-dose rosuvastatin and clarithromycin cause severe toxicity such as acute liver injury and rhabdomyolysis?
Case Report (n=1)
Does concurrent use of high-dose rosuvastatin and clarithromycin cause severe toxicity such as acute liver injury and rhabdomyolysis?
This case highlights a rare but clinically important drug-drug interaction between rosuvastatin and clarithromycin leading to severe liver injury and rhabdomyolysis, which may be under-recognized in elderly or critically ill patients.
No takes yet. Share an insight, caveat, or question.
Alerts clinicians to interaction risk in elderly patients; leaves open need for systematic pharmacovigilance studies.
Nithin Tumkur Prasad (2026) conducted a case report in Acute liver injury and rhabdomyolysis (n=1). Concurrent rosuvastatin and clarithromycin was evaluated on Development of marked transaminase elevation and severe rhabdomyolysis. Concurrent use of high-dose rosuvastatin and clarithromycin in a 69-year-old male led to marked transaminase elevation and severe rhabdomyolysis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: